CVRx (NASDAQ:CVRX - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Tuesday, October 29th. Analysts expect CVRx to post earnings of ($0.45) per share for the quarter. CVRx has set its Q3 2024 guidance at EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.
CVRx (NASDAQ:CVRX - Get Free Report) last posted its quarterly earnings data on Monday, July 29th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). The firm had revenue of $11.81 million for the quarter, compared to analysts' expectations of $11.84 million. CVRx had a negative return on equity of 77.62% and a negative net margin of 122.52%. During the same quarter last year, the firm posted ($0.56) earnings per share. On average, analysts expect CVRx to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of CVRx stock opened at $10.26 on Tuesday. The stock has a market cap of $221.57 million, a P/E ratio of -4.15 and a beta of 1.26. The stock's 50 day simple moving average is $8.61 and its 200-day simple moving average is $9.88. CVRx has a 1-year low of $6.40 and a 1-year high of $33.13. The company has a debt-to-equity ratio of 0.53, a current ratio of 10.08 and a quick ratio of 8.85.
Several research analysts have recently weighed in on CVRX shares. Canaccord Genuity Group boosted their target price on CVRx from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, July 30th. Lake Street Capital restated a "buy" rating and set a $12.00 target price on shares of CVRx in a report on Monday, August 26th. Cantor Fitzgerald started coverage on CVRx in a report on Tuesday, September 10th. They set an "overweight" rating and a $14.00 target price on the stock. Piper Sandler lowered their target price on CVRx from $15.00 to $13.00 and set an "overweight" rating on the stock in a report on Tuesday, July 30th. Finally, Craig Hallum decreased their price objective on CVRx from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Thursday, July 11th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, CVRx currently has an average rating of "Moderate Buy" and an average target price of $13.67.
Get Our Latest Analysis on CVRx
In other CVRx news, CEO Kevin Hykes acquired 30,000 shares of the firm's stock in a transaction that occurred on Monday, August 5th. The shares were purchased at an average cost of $8.36 per share, for a total transaction of $250,800.00. Following the completion of the acquisition, the chief executive officer now owns 30,000 shares of the company's stock, valued at approximately $250,800. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have acquired 38,500 shares of company stock worth $322,545. Insiders own 18.90% of the company's stock.
CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CVRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVRx wasn't on the list.
While CVRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.